Evidence map›Paper›PMID 30968156›Full record

ArticleInternational journal of oncology2019

Vitamin D and its low calcemic analogs modulate the anticancer properties of cisplatin and dacarbazine in the human melanoma A375 cell line.

Anna Piotrowska, Justyna Wierzbicka, Agnieszka Rybarczyk, Robert C Tuckey, Andrzej T Slominski, Michał A Żmijewski

Open access · bronzeAbstract read
In one paragraph

Article in International journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. 1,24,25(OH)Scientific reports · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Vitamin D regulation of energy metabolism in cancer.British journal of pharmacology · 2022
    Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Anna PiotrowskaDepartment of Histology, Faculty of Medicine, Medical University of Gdansk, 80‑211 Gdansk, Poland.
Justyna WierzbickaDepartment of Histology, Faculty of Medicine, Medical University of Gdansk, 80‑211 Gdansk, Poland.
Agnieszka RybarczykDepartment of Histology, Faculty of Medicine, Medical University of Gdansk, 80‑211 Gdansk, Poland.
Robert C TuckeySchool of Molecular Sciences, Faculty of Science, The University of Western Australia, Perth, Western Australia 6009, Australia.
Andrzej T SlominskiDepartment of Dermatology, Cancer Chemoprevention Program, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Michał A ŻmijewskiDepartment of Histology, Faculty of Medicine, Medical University of Gdansk, 80‑211 Gdansk, Poland.
Gdańsk Medical University · PLUniversity of Alabama at Birmingham · USUniversity of Western Australia · AU

Funding

Mechanism of action and function of novel secosteroid 20(OH)D3 in the skinR01AR073004 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANDRZEJ T SLOMINSKI · 2018 to 2026
$2.9M
Significance of metabolic activation of lumisterol in the skinR01AR071189 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SLOMINSKI, ANDRZEJ T · 2017 to 2021
$1.6M
CYP11A1-derived secosteroids as therapeutic agents in UVB induced skin cancerI01BX004293 · VA · BIRMINGHAM VA MEDICAL CENTER · PI SLOMINSKI, ANDRZEJ T · 2019 to 2025
–
BLRD VA I01 BX004293NIAMS NIH HHS R01 AR071189NIAMS NIH HHS R01 AR073004
6 · The paper itself

Abstract

Melanoma represents a significant challenge in cancer treatment due to the high drug resistance of melanomas and the patient mortality rate. This study presents data indicating that nanomolar concentrations of the hormonally active form of vitamin D, 1α,25‑dihydroxyvitamin D3 [1α,25(OH)2D3], its non‑calcemic analogues 20S‑hydroxyvitamin D3 and 21‑hydroxypregnacalciferol, as well as the low‑calcemic synthetic analog calcipotriol, modulate the efficacy of the anticancer drugs cisplatin and dacarbazine. It was observed that vitamin D analogs sensitized melanoma A375 cells to hydrogen peroxide used as an inducer of oxidative stress. On the other hand, only 1α,25(OH)2D3 resulted in a minor, but significant effect on the proliferation of melanoma cells treated simultaneously with dacarbazine, but not cisplatin. Notably, cisplatin (300 µM) exhibited a higher overall antiproliferative activity than dacarbazine. Cisplatin treatment of melanoma cells resulted in an induction of apoptosis as demonstrated by flow cytometry (accumulation of cells at the subG1 phase of the cell cycle), whereas dacarbazine caused G1/G0 cell cycle arrest, with the effects being improved by pre‑treatment with vitamin D analogs. Treatment with cisplatin resulted in an initial increase in the level of reactive oxygen species (ROS). Dacarbazine caused transient stimulation of ROS levels and the mitochondrial membrane potential (Δψm) (after 1 or 3 h of treatment, respectively), but the effect was not detectable following prolonged (24 h) incubation with the drug. Vitamin D exhibited modulatory effects on the cells treated with dacarbazine, decreasing the half maximal inhibitory concentration (IC50) for the drug, stimulating G1/G0 arrest and causing a marked decrease in Δψm. Finally, cisplatin, dacarbazine and 1α,25(OH)2D3 displayed modulatory effects on the expression of ROS and vitamin D‑associated genes in the melanoma A375 cells. In conclusion, nanomolar concentrations of 1,25(OH)2D3 only had minor effects on the proliferation of melanoma cells treated with dacarbazine, decreasing the relative IC50 value. However, co‑treatment with vitamin D analogs resulted in the modulation of cell cycle and ROS responses, and affected gene expression, suggesting possible crosstalk between the signaling pathways of vitamin D and the anticancer drugs used in this study.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsApoptosisCell Line, TumorCisplatinDacarbazineDrug Resistance, NeoplasmDrug SynergismG1 Phase Cell Cycle CheckpointsHumansInhibitory Concentration 50MelanomaReactive Oxygen SpeciesSkin NeoplasmsVitamin DCisplatinDacarbazineReactive Oxygen SpeciesVitamin Dchemotherapycisplatindacarbazinehydroxyvitamin Dmelanomaoxidative stressreactive oxygen speciesvitamin Dvitamin D analogs

Identifiers

PMID30968156
PMCPMC6411347
OpenAlexW2916527180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.